Functions of Polypeptide N-acetylgalactosaminyltransferase (GALNT)

Glycosylation modification is an important post-translational modification of proteins. According to the different ways of linking the sugar chain and protein, glycosylation modification is mainly divided into two types: N-glycosylation and O-glycosylation. One of the most common O-glycosylation modifications is mucin-type O-glycosylation. With continuous research, more and more tumor markers are being discovered. These include several members of the GALNT family, which is the initiating enzyme that catalyzes mucin-type O-glycosylation. It affects the O-glycosylation of mucins, thereby influencing tumor cell genesis, prognosis, proliferation, and migration. To date, 20 isoforms of GALNT have been identified in humans. There are lots of research reports on GALNT related to cancer and other diseases.

GALNT Modification Services at CD BioGlyco

CD BioGlyco is committed to being a reliable GALNT gene modification service partner. We have rich experience in cell lines and animal model construction.

Fig.1 One-stop GALNT gene modification process. (CD BioGlyco)

• Various GALNT gene modification service
  Animal and cell line models are powerful tools for biomedical research. We have various types of mice and cell line models such as cancer cells, bone cells, etc. According to customers' needs, we develop Gene Editing Programs and construct gene modification models. Through overexpression, knockout, knockdown, and other different gene modification methods, we study the specific substrate of GALNT, its physiological function, and its application in the treatment of diseases.

• Technologies for editing service
  We have a wide range of technologies for gene editing, including Zinc-Finger Nuclease (ZFN) and CRISPR/Cas9. We study the function of GALNT and its application in various diseases by constructing mouse or cell line models such as GALNT knockout, overexpression, etc.

Published Data

Paper Title: B4GALNT3 regulates glycosylation of sclerostin and bone mass

Technology: Gene Knockout, Gene Overexpression, Gene Silencing

Journal: EBioMedicine

IF: 11.1

Published: 2023

Results: B4GALNT3 expresses β-1,4-N-acetylgalactosaminyltransferase 3. Serum total sclerostin levels were elevated but serum LDN-glycosylated sclerostin levels were decreased in B4GALNT3 knockout mice compared to controls. The silencing of B4GALNT3 decreased the levels of LDN-glycosylated sclerostin, whereas overexpression of B4GALNT3 decreased the levels. B4GALNT3-mediated LDN-glycosylation of sclerostin may be a target for bone-specific osteoporosis.

Fig. 2 Changes in sclerostin levels in B4galnt3 knockout mice. (Movérare-Skrtic, et al., 2023)

Applications

• GALNT has diverse functions in different biological behaviors of tumor cells. Technologies for GALNT gene editing are used to develop new means of suppressing cancer cells.
• Technologies for GALNT gene editing are important for the study of the regulatory mechanisms of glycosylation and the functional roles of glycoproteins in life activities.
• Technologies for GALNT gene editing are used for the role of GALNT in inflammation and other diseases, which is expected to provide possible ideas for the search for novel markers and drug targets.

Advantages

• We optimize the experimental conditions. We improve the positive rate while reducing cytotoxicity, and have high editing efficiency and low off-target rate.
• We have a professional gene editing team to provide clients with experimental design, troubleshooting, data analysis, and other services.
• We provide a one-stop service for GALNT gene editing. Sequence design, vector construction, mutant construction, and other experiments can be completed.

CD BioGlyco has undergone continuous research to minimize the time required to prepare gene-edited cells and animal models. We use optimized technologies for gene editing to precisely modify genes. If you are interested in our GALNT gene modification service, please feel free to contact us.

Reference:

1. Movérare-Skrtic, S.; et al. B4GALNT3 regulates glycosylation of sclerostin and bone mass. EBioMedicine. 2023, 91: 104546.